Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Astellas commits to new focus on oncology

Astellas commits to new focus on oncology

21st April 2010

Astellas has confirmed that it will be aiming to broaden its presence in the European oncology sector in the coming years as it looks to sustain its corporate growth.

Marking the fifth anniversary of the pharmaceutical company’s foundation, Astellas Pharma Europe has identified cancer treatment as its sixth franchise focus, following on from its success in the transplantation, urology, dermatology, anti-infective and pain relief sectors.

The company has already launched the prostate cancer therapy Eligard as part of this new commitment, while a number of promising molecules and treatments are currently in Astellas’ developmental pipeline.

It also highlighted the recent acquisition of biotech subsidiary Agensys as another move which will serve to broaden its oncology offerings.

Masao Yoshida, president and chief executive officer of Astellas Pharma Europe, said: “Our vision at Astellas is focused on changing tomorrow for patients. It is very exciting for the company to begin to focus on the area of oncology.”

Astellas is also currently engaged in talks with OSI Pharmaceuticals over a potential takeover of the company, a move which will further strengthen its oncology portfolio.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.